Mondias - NHP TSXV - Corporate Presentation

1. Corporate
Presentation
June 2019
TSXV | NHP

2. FORWARD-LOOKING
STATEMENTS
This presentation contains forward-looking statements that reflect the Company’s
current expectations regarding future events. There’s a risk that expectations, and the
forward-looking statements on which they are based, will not prove to be accurate.
Readers are cautioned not to place undue reliance on forward-looking statements, as they involve risks and
uncertainties that could make actual results differ materially from those projected therein and depend on a
number of factors, including, but not limited to, the Company’s lack of history of profitability, the availability of
future financing, the Company’s ability to protect its intellectual property rights and obtain patents, dependence
on key personnel, the competitiveness of the marketplace, technological obsolescence, share price volatility
and other risks described from time to time in the Company’s filings.
While Mondias acknowledges that future events and developments may cause its views to change, it
undertakes no obligation to update forward-looking statements, except as required by applicable securities
laws.
2
TSXV | NHP

3. > Mondias Natural Products (TSXV: NHP) specializes
in the commercialization and development of
evidence-based botanical products for the bio-
agriculture and healthcare markets.
> Mondias is focused on large, growing markets,
such as biopesticides, biostimulants, agriculture,
cannabis, sleeping aids, wound healing, acne, nail
fungus, and hair loss.
> The Company has a strong IP portfolio, including
53 products with Health Canada Natural Product
Numbers (NPNs) and 4 patents.
> Mondias generates revenues by selling its products
through its Holizen division and web platform
(www.holizen.com), as well as through retailers,
distributors, and co-branding partnerships.
-
A GROWTH STORY
3
TSXV | NHP

4. Jean-Philippe Gravel, MBA
President and Chief Executive Officer
Over 14 years of experience in business management
and development, having held strategic roles in the
medical, pharmaceutical and banking industries.
Jamil Samsatly, M.Sc.
Chief Scientific Officer
Over 10 years of experience in global sustainable
agriculture, healthy agri-food systems and molecular
biotechnology.
Sabino Di Paola, CPA, CA
Chief Financial Officer
Over 10 years of experience in audit, finance and
accounting as an auditor for PricewaterhouseCoopers
and BDO Canada.
L. Derek Lindsay, MBA
Vice President, Corporate Development
Expertise in raising equity and financing projects,
structuring creative strategic partnerships, increasing
investor awareness and completing acquisitions.
André Rancourt
Executive Chairman and Co-Founder of Mondias
(previously CEO and Chairman for Tetra Biopharma)
Louis Doyle
Executive Director of Quebec Bourse
(previously VP of TSX Venture Exchange, Montreal)
Frank Palantoni
CEO of LabM2
(previously President of Pet and Life Science, Global CEO of
Gerber Products and CEO of Novartis Consumer Health)
Michel Timperio
President - Cannabis Business, Neptune Wellness Solutions
Bertrand Venne
Consultant
(previously COO at Fromage Côté, President and CEO of
Entreprises Pâtes et Croûtes LB and Aliments Novali)
BOARD OF
DIRECTORS
LEADERSHIP -
Broad expertise in
natural products
development and
commercialization
-
4

5. Biopesticides
Biostimulants
Grey mould and powdery mildew postharvest infections1 causes global
annual economic losses of $10 billion to $100 billion
Sleeping aids
Global sleeping aids market valued at $69.5 billion in 2017, expected to
reach $101.9 billion by 20232
2020
Insect repellent
Global insect repellent market expected to grow at a CAGR of 6.5%
to reach $7 billion by 20263
Acne
Global acne drug market expected to grow at a CAGR of 4.2%
to reach $5.9 billion by 20254
Nail fungus
Global nail fungus market expected to grow at a CAGR of 7.6%
to reach $6.7 billion by 20265
Wound healing
Global wound healing market valued at $23.3 billion in 2016, expected
to reach $35 billion by 20256
Hair loss
Global hair loss market valued at $7.3 billion in 2015, expected
to reach $11.8 billion by 20247
FOCUS ON LARGE,
GROWING MARKETS
2019
5
1 L. Hua et al., 2018; 2 P&S Market Research, May 2018; 3 Transparency Market Research, April 2018;
4 Grand View Research, Inc., November 2018; 5 Persistence Market Research, July 2018;
6 Transparency Market Research, March 2018; 7 Grand View Research, Inc., June 2016.
TSXV | NHP

6. > The global pesticide market, which includes synthetic
pesticides and biopesticides, is expected to grow to $90 billion
by 20232.
> Synthetic pesticides pollute ecosystems, cause human health
problems (recent example of Glyphosate or Roundup) and
create pest resistance.
> The global biopesticides market is anticipated to grow at a
CAGR of about 21.2% during 2017-20253, due to:
- Increasing demand for organic food
- Awareness about harmful effect of synthetic pesticides
- Novel products
- Easy decomposability
- Advent of new kind of pests
- Growers seeking eco-friendly alternatives.
1 L. Hua et al., 2018;
2 Research and Markets, August 2018;
3 Inkwood Research, Sept. 2017.
A BETTER
ALTERNATIVE
TO SYNTHETIC
PESTICIDES?
-
Biopesticides
Biostimulants
+$10 billion
market
opportunity1
-
6
TSXV | NHP

7. > CELEXT07 bio-defense stimulant proven to be a superior,
eco-friendly alternative to synthetic pesticides.
> Developed and tested with McGill University to prevent and fight diseases
affecting crops, such as grey mould (viticulture, vegetables) and powdery mildew (cannabis).
> Successful large-scale greenhouse trials on tomatoes, lettuce and hops.
> Positive field tests on cannabis plants with leading cannabis producer.
> Patent pending on herbal phytosanitary composition and methods for the prevention and
treatment of plant infections in Canada, the U.S., Europe, China, Australia, Brazil and the
World Intellectual Property Organization (WIPO).
CELEXT07 BOTANICAL EXTRACT
-
Mondias’
superior eco-
friendly
alternative to
synthetic
pesticides
-
7
TSXV | NHP

8. NEXT STEPS
> Product is ready to market.
> Ongoing product testing and discussions
with leading cannabis producers, as well as
agriculture and horticulture companies.
> Strategy to develop co-branding
partnerships.
> Production capacity secured to meet
demand from potential clients.
-
CELEXT07
-
Production
capacity
secured and
product ready
to market
-
8
TSXV | NHP

9. SLEEP DISORDERS ARE:
> Common: about 50% of adults
experience occasional bouts of
insomnia and 1 in 10 suffers from
chronic insomnia2.
> Diverse: insomnia, sleep apnea,
restless legs syndrome, narcolepsy.
> Likely to increase: 24/7 society.
ANXIETY AND DEPRESSIVE
DISORDERS ARE:
> The two most common psychiatric
illnesses across the globe.
> The main causes of sleep deprivation.1 P&S Market Research, May 2018;
2 IndustryARC, April 2018.
-
SLEEP DEPRIVATION
AND ANXIETY: A
GROWING PROBLEM
-
Combined
+$100 billion
sleeping aid
and anxiety
market by
20231
-
9
TSXV | NHP

10. > Mondias developed its first natural health product line with
proven efficacy for sleep and anxiety disorders.
> Ongoing research to assess if our product can induce
restorative sleep in patients suffering from chronic pain.
> Patent pending on herbal compositions for the treatment of
sleep and dream‐related disorders in the U.S. and WIPO.
NEXT STEP
> Launch of our new product line planned for 2019.
SLEEPING AID PRODUCT LINE
-
Proven efficacy
for sleep and
anxiety
disorders
-
10
TSXV | NHP

11. Mondias has 53 Natural Product Numbers
(NPNs) registered with Health Canada in
various health market segments. It has
commercialized approximately 30 products
in the following market segments:
-
Goal is to bring
these products
to market in the
next three
years
-
-
NATURAL
PRODUCTS PIPELINE
> Bone health
> Stress and anxiety
> Cardiovascular health
> Hair health
> Pain management
> Skin health
> Joint pain
> Digestive health
> Energy and vitality
11
TSXV | NHP

12. > Mondias generates revenues by selling its
consumer products through natural health
product stores via its Holizen division.
> Expanding into the rest of Canada and
grow sales in Quebec by stepping up
promotional activities.
> Sales representation agreement signed
with a leading company specializing in
retail sales of natural health products in
Ontario.
> Ontario has 450 natural health products
stores, compared to 200 in Quebec.
> Next step includes expansion into
Western Canada.
HOLIZEN -
2019 expansion
could generate
significant
growth
-
12
TSXV | NHP

13. FINANCIAL
PERFORMANCE
-
Gross margin
of 77% in Q1
2019
-
13
Fiscal year ended November 30 2018 2017
Revenues
(no comparative figure as F2017 consisted of a
single quarter)
$537,000 n/a
Q1 ended February 28 2019 2018
Revenues $127,154 $127,791
Gross margin 77% 69%
Cash balance
(as of February 28, 2019)
$896,341
Focusing on growing revenue
Launching new products
Commercializing IP portfolio
TSXV | NHP

14. > CELEXT07: form co-branding partnerships with leaders in the
agriculture, horticulture and cannabis markets.
> Sleeping aid product line: launch planned in 2019.
> Looking at complementary acquisitions to boost revenues,
profitability and product offering.
> Expand Holizen’s operations into the rest of Canada.
> Continue to develop other products with the goal of bringing them
to market.
GROWTH STRATEGY -
Focus is on
lead products
and short-term
growth
opportunities
-
14
TSXV | NHP

15. TSX Venture Exchange
(On November 26, 2018, Mondias completed a
reverse takeover of Element 79 Capital Inc.)
NHP
Shares outstanding 63.1M
Warrants
(exercice price: $0.25)
6.9M
Options
(average exercice price: $0.235)
3.6M
Fully diluted shares 73.6M
Stock price
(as of May 31, 2019)
$0.21
Insider ownership 36.3M
(58%)
CAPITALIZATION
-
Committed
insiders hold
58% of the
shares
-
15
TSXV | NHP

16. -
CONTACT
INFORMATION
Jean-Philippe Gravel
Chief Executive Officer
-
1 866-722-2442
jpgravel@mondias.ca
L. Derek Lindsay
VP, Corporate Development
-
514-594-2372
dlindsay@mondias.ca